TISIDB

Summary
Symbol	LAMB1
Name	laminin, beta 1
Aliases	cutis laxa with marfanoid phenotype; LIS5; laminin B1 chain; Laminin-8 subunit beta; Laminin-6 subunit beta; ......
Chromosomal Location	7q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Secreted, extracellular space, extracellular matrix, basement membrane. Note=Major component.
Domain	PF00053 Laminin EGF domain PF00055 Laminin N-terminal (Domain VI)
Function	Binding to cells via a high affinity receptor, laminin is thought to mediate the attachment, migration and organization of cells into tissues during embryonic development by interacting with other extracellular matrix components. Involved in the organization of the laminar architecture of cerebral cortex. It is probably required for the integrity of the basement membrane/glia limitans that serves as an anchor point for the endfeet of radial glial cells and as a physical barrier to migrating neurons. Radial glial cells play a central role in cerebral cortical development, where they act both as the proliferative unit of the cerebral cortex and a scaffold for neurons migrating toward the pial surface.

> Gene Ontology [ TOP ]
Biological Process	GO:0001704 formation of primary germ layer GO:0001706 endoderm formation GO:0007369 gastrulation GO:0007492 endoderm development GO:0008347 glial cell migration GO:0021537 telencephalon development GO:0021543 pallium development GO:0021795 cerebral cortex cell migration GO:0021799 cerebral cortex radially oriented cell migration GO:0021801 cerebral cortex radial glia guided migration GO:0021812 neuronal-glial interaction involved in cerebral cortex radial glia guided migration GO:0021885 forebrain cell migration GO:0021987 cerebral cortex development GO:0022029 telencephalon cell migration GO:0022030 telencephalon glial cell migration GO:0030198 extracellular matrix organization GO:0030335 positive regulation of cell migration GO:0030900 forebrain development GO:0031589 cell-substrate adhesion GO:0034446 substrate adhesion-dependent cell spreading GO:0035987 endodermal cell differentiation GO:0040017 positive regulation of locomotion GO:0042063 gliogenesis GO:0042476 odontogenesis GO:0043062 extracellular structure organization GO:0050673 epithelial cell proliferation GO:0050678 regulation of epithelial cell proliferation GO:0050679 positive regulation of epithelial cell proliferation GO:0051272 positive regulation of cellular component movement GO:2000147 positive regulation of cell motility
Molecular Function	GO:0005201 extracellular matrix structural constituent
Cellular Component	GO:0005578 proteinaceous extracellular matrix GO:0005604 basement membrane GO:0005605 basal lamina GO:0005606 laminin-1 complex GO:0005607 laminin-2 complex GO:0043256 laminin complex GO:0043257 laminin-8 complex GO:0043259 laminin-10 complex GO:0044420 extracellular matrix component

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04151 PI3K-Akt signaling pathway hsa04510 Focal adhesion hsa04512 ECM-receptor interaction
Reactome	R-HSA-422475: Axon guidance R-HSA-1474228: Degradation of the extracellular matrix R-HSA-1266738: Developmental Biology R-HSA-3000178: ECM proteoglycans R-HSA-1474244: Extracellular matrix organization R-HSA-373760: L1CAM interactions R-HSA-3000157: Laminin interactions R-HSA-8874081: MET activates PTK2 signaling R-HSA-8875878: MET promotes cell motility R-HSA-3000171: Non-integrin membrane-ECM interactions R-HSA-162582: Signal Transduction R-HSA-6806834: Signaling by MET

> KEGG and Reactome Pathway

[ TOP ]

KEGG

hsa04151 PI3K-Akt signaling pathway
hsa04510 Focal adhesion
hsa04512 ECM-receptor interaction

Reactome

R-HSA-422475: Axon guidance
R-HSA-1474228: Degradation of the extracellular matrix
R-HSA-1266738: Developmental Biology
R-HSA-3000178: ECM proteoglycans
R-HSA-1474244: Extracellular matrix organization
R-HSA-373760: L1CAM interactions
R-HSA-3000157: Laminin interactions
R-HSA-8874081: MET activates PTK2 signaling
R-HSA-8875878: MET promotes cell motility
R-HSA-3000171: Non-integrin membrane-ECM interactions
R-HSA-162582: Signal Transduction
R-HSA-6806834: Signaling by MET

Summary
Symbol	LAMB1
Name	laminin, beta 1
Aliases	cutis laxa with marfanoid phenotype; LIS5; laminin B1 chain; Laminin-8 subunit beta; Laminin-6 subunit beta; ......
Chromosomal Location	7q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between LAMB1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	LAMB1
Name	laminin, beta 1
Aliases	cutis laxa with marfanoid phenotype; LIS5; laminin B1 chain; Laminin-8 subunit beta; Laminin-6 subunit beta; ......
Chromosomal Location	7q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of LAMB1 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	Second most enriched score: 0.58	Sensitive to T cell-mediated killing
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	LAMB1
Name	laminin, beta 1
Aliases	cutis laxa with marfanoid phenotype; LIS5; laminin B1 chain; Laminin-8 subunit beta; Laminin-6 subunit beta; ......
Chromosomal Location	7q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of LAMB1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.727	0.0851
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.666	0.803
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.768	0.687
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.113	0.772
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.299	0.916
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.123	0.973
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.249	0.692
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.404	0.854
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.999	0.678
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.162	0.944
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	1.798	0.566
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.272	0.0191

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of LAMB1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	5.9	-5.9	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	7.1	-7.1	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	7.4	1.4	6	0.177
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	7.4	1.7	5.7	0.231
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	4.8	17.6	-12.8	0.307
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	16.7	-16.7	0.429
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	7.7	18.2	-10.5	0.576
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	3.7	-3.7	0.415
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	7.1	-7.1	0.467
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	LAMB1
Name	laminin, beta 1
Aliases	cutis laxa with marfanoid phenotype; LIS5; laminin B1 chain; Laminin-8 subunit beta; Laminin-6 subunit beta; ......
Chromosomal Location	7q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of LAMB1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	LAMB1
Name	laminin, beta 1
Aliases	cutis laxa with marfanoid phenotype; LIS5; laminin B1 chain; Laminin-8 subunit beta; Laminin-6 subunit beta; ......
Chromosomal Location	7q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of LAMB1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by LAMB1. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	LAMB1
Name	laminin, beta 1
Aliases	cutis laxa with marfanoid phenotype; LIS5; laminin B1 chain; Laminin-8 subunit beta; Laminin-6 subunit beta; ......
Chromosomal Location	7q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of LAMB1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	LAMB1
Name	laminin, beta 1
Aliases	cutis laxa with marfanoid phenotype; LIS5; laminin B1 chain; Laminin-8 subunit beta; Laminin-6 subunit beta; ......
Chromosomal Location	7q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of LAMB1 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	LAMB1
Name	laminin, beta 1
Aliases	cutis laxa with marfanoid phenotype; LIS5; laminin B1 chain; Laminin-8 subunit beta; Laminin-6 subunit beta; ......
Chromosomal Location	7q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between LAMB1 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	LAMB1
Name	laminin, beta 1
Aliases	cutis laxa with marfanoid phenotype; LIS5; laminin B1 chain; Laminin-8 subunit beta; Laminin-6 subunit beta; ......
Chromosomal Location	7q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting LAMB1 collected from DrugBank database.

> Drugs from DrugBank database

[ TOP ]

Details on drugs targeting LAMB1.

ID	Name	Drug Type	Targets	#Targets
DB06245	Lanoteplase	Biotech	ANXA2, CALR, CANX, CLEC3B, F10, FGA, FN1, KLK1, KRT8, LAMA1, LAMA3 ......	17

Browse LAMB1